Warfarin drug interactions: the list, the mechanism, and what to check before you sign

The antibiotics that most reliably raise the INR are trimethoprim/sulfamethoxazole, metronidazole, fluoroquinolones such as ciprofloxacin and levofloxacin, and the macrolides clarithromycin and erythromycin. Rifampin does the opposite and drops the INR through enzyme induction. The usual approach when one of these is unavoidable is to recheck the INR within three to five days of starting the course, and again within three to five days of finishing it, because the interaction unwinds as well as builds.

Two things make antibiotic interactions easy to miss. The first is that the infection itself, and the reduced oral intake that often comes with it, moves the INR in the same direction, so the effect is larger than the drug interaction alone would predict. The second is that the prescription often comes from someone other than the clinician managing the anticoagulation, in urgent care or a walk-in clinic, where the warfarin may not be on the visible list at all.

Amiodarone inhibits CYP2C9, the enzyme that clears S-warfarin, the more pharmacologically potent of the two warfarin isomers, and also inhibits CYP1A2 and CYP3A4. The result is reduced warfarin clearance and a rising INR. What makes this interaction different from the antibiotic ones is the timeline: amiodarone has an extremely long half life, so the effect builds over weeks rather than days and does not disappear quickly when amiodarone is stopped.

Because the direction is predictable, an empiric warfarin dose reduction at the time amiodarone is started, followed by weekly INR checks until the value is stable, is widely described in the literature rather than waiting for the INR to drift. The specific reduction and monitoring interval belong to the treating clinician and the current labeling, not to a reference page. What a decision-support tool can do is make sure the interaction is raised at all, at the moment the amiodarone is being added.

This is the category that catches experienced clinicians, because the safety net most teams rely on, the INR, does not move. NSAIDs are the clearest example: ibuprofen, naproxen, diclofenac and ketorolac inhibit platelet function and injure the gastric mucosa, so a patient can bleed at a perfectly therapeutic INR. Aspirin at antiplatelet doses does the same thing, and dual antiplatelet therapy compounds it further.

SSRIs and SNRIs belong here too. They deplete platelet serotonin, which impairs aggregation, and the combination of an SSRI, an NSAID and warfarin is a well documented high risk trio in older patients. None of this shows up on a coagulation panel. It shows up as a gastrointestinal bleed. A check that looks only at INR-moving interactions will report a clean result for a genuinely dangerous regimen, which is why interaction screening and bleeding risk assessment are different questions.

Not in the same way, and assuming they do is a common source of error in both directions. Apixaban, rivaroxaban and edoxaban are substrates of CYP3A4 and P-glycoprotein, and dabigatran is a P-glycoprotein substrate that does not depend on CYP metabolism at all. So the interaction list changes: strong dual inhibitors such as ketoconazole and ritonavir matter a great deal, strong inducers such as rifampin and carbamazepine reduce anticoagulant exposure, and most of the vitamin K and gut flora issues that dominate warfarin management simply disappear.

What carries across unchanged is the pharmacodynamic bleeding risk. NSAIDs, antiplatelets and SSRIs raise bleeding risk on a direct oral anticoagulant exactly as they do on warfarin, and here there is no INR at all to provide false reassurance. Renal function also becomes a dosing input rather than a background consideration, which is why an interaction check and a renal dose check really belong in the same place.

A list like the one above is useful for pattern recognition and useless at 4:50pm when the patient in front of you is on nine medications and you are adding a tenth. Prescriber.io takes the actual regimen, checks it for drug-drug interactions, and returns the flag with the mechanism in plain language and the source cited, alongside contraindications, allergy blockers, renal and hepatic dose considerations, and guideline-based alternatives, in one card rather than four separate lookups.

It is decision-support for licensed US clinicians, not autonomous prescribing. Every flag is a prompt for you to consider. You verify against the official labeling and your own institutional references, exercise clinical judgment, and sign. The value is that the check happens at all, on every prescription, including the ones written when the clinic is running an hour behind.